Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Afamelanotide - Clinuvel Pharmaceuticals

Drug Profile

Afamelanotide - Clinuvel Pharmaceuticals

Alternative Names: [Nle4,DPhe7]-alpha-MSH; CUV-1647; EPT-1647; Melanotan I; Melanotan™; MT I; Scenesse

Latest Information Update: 06 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Arizona
  • Developer Clinuvel Pharmaceuticals
  • Class Antineoplastics; Antipyretics; Melanocyte-stimulating hormones; Peptides; Skin disorder therapies
  • Mechanism of Action Melanocortin type 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Erythropoietic protoporphyria; Pemphigus; Urticaria
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythropoietic protoporphyria
  • Phase II Pemphigus; Vitiligo
  • Suspended Polymorphus light eruptions; Urticaria
  • Discontinued Acne vulgaris; Actinic keratosis; Photodamage; Squamous cell cancer

Most Recent Events

  • 30 Oct 2019 Afamelanotide is still in phase III development for Erythropoietic protoporphyria (Prevention) in Australia (SC)
  • 30 Oct 2019 Australian Therapeutic Goods Administration (TGA) enables priority registration pathway for afamelanotide for Erythropoietic protoporphyria (In adults, Prevention)
  • 30 Oct 2019 Clinuvel Pharmaceuticals intends to submit scientific dossier for Erythropoietic protoporphyria (Prevention) to the Australian TGA in Q1 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top